WO2016110168A1 - 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement du diabète sucré ou son application comme produit de soin de santé et médicament - Google Patents

20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement du diabète sucré ou son application comme produit de soin de santé et médicament Download PDF

Info

Publication number
WO2016110168A1
WO2016110168A1 PCT/CN2015/096991 CN2015096991W WO2016110168A1 WO 2016110168 A1 WO2016110168 A1 WO 2016110168A1 CN 2015096991 W CN2015096991 W CN 2015096991W WO 2016110168 A1 WO2016110168 A1 WO 2016110168A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
ginsenoside
medicament
group
diabetes
Prior art date
Application number
PCT/CN2015/096991
Other languages
English (en)
Chinese (zh)
Inventor
富力
王凯乾
王硕
惠敏
刘正贤
鲁岐
柳洋
付强
鲁明明
冯雪
盖鑫
刘国友
付文斐
周庆丰
郭永学
Original Assignee
富力
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富力 filed Critical 富力
Publication of WO2016110168A1 publication Critical patent/WO2016110168A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)

Definitions

  • the invention belongs to the field of medicine, relates to a medicine or health food for treating diabetes, and particularly relates to an application of a traditional Chinese medicine ginseng extract component in relieving and/or treating diabetes medicine or health food.
  • Diabetes is a chronic disease that is a serious health hazard and is one of the major health problems facing civilization today. Diabetes can be divided into insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin-dependent diabetes mellitus (NIDDM, type II).
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • Oral anti-diabetic drugs are classified according to the mechanism of action, mainly in the following categories: 1 insulin and insulin analogs; 2 insulin-promoting drugs; 3 aldose reductase inhibitors; 4 insulin sensitizers; 5 drugs for inhibiting glucose absorption, Such as ⁇ -glucosidase inhibitors.
  • 1 insulin and insulin analogs 2 insulin-promoting drugs
  • 3 aldose reductase inhibitors 3 aldose reductase inhibitors
  • 4 insulin sensitizers insulin sensitizers
  • 5 drugs for inhibiting glucose absorption Such as ⁇ -glucosidase inhibitors.
  • the combination of drugs in the treatment of type 2 diabetes has increased the physiological and economic burden of patients.
  • oral hypoglycemic drugs for treating diabetes can temporarily control the blood sugar of patients, but it does not completely prevent the development of the disease and complications. Therefore, the development of new mechanisms of action or new types of high-efficiency and low-toxic anti-diabetic drugs has become the focus of new drug research and development in the world.
  • ginseng Chinese medicine modern medical research shows that the main functions and effects of ginseng are: the role of the central nervous system, anti-cancer anti-tumor effect, immune function regulation, anti-diabetes effect, enhance liver function, cardiovascular and cerebrovascular disorders Improvement, anti-atherosclerosis, blood pressure regulation, and menopausal disorders And anti-osteoporosis, anti-fatigue, anti-oxidation, anti-aging and so on.
  • ginsenoside is widely studied and used. Among them, 20(R)-ginsenoside Rg3 is the most attractive. It is the main active ingredient of ginseng and has good safety. It has been made into anti-tumor oral preparation. It has been used clinically and has been intensively studied as an injection.
  • the inventors used advanced separation and purification technology to extract 20(R)-ginsenoside Rg3, an effective component for treating diabetes, from ginseng herbs, and can provide a highly effective and low-toxic drug for diabetic patients.
  • the object of the present invention is to provide a 20(R)-ginsenoside Rg3 for alleviating or/and treating the performance and efficacy of a diabetic disease, and providing 20(R) for the technical problems existing in the existing drugs or health care products for treating diabetes diseases.
  • an aspect of the present invention provides an application of 20(R)-ginsenoside Rg3 in the preparation of a medicament or a health care product for relieving or/and treating a diabetic disease.
  • the drug consists of 20(R)-ginsenoside Rg3 and a pharmaceutically acceptable carrier.
  • the content of the 20(R)-ginsenoside Rg3 is 1% to 98%; preferably 30 to 80%, and more preferably 60%.
  • the 20(R)-ginsenoside Rg3 content is ⁇ 1%, preferably ⁇ 30%, further preferably ⁇ 60%, still more preferably ⁇ 80%, still more preferably ⁇ 98%.
  • pharmaceutically acceptable carriers are generally approved by health care professionals for this purpose and as inactive ingredients of the agent.
  • a compilation of pharmaceutically acceptable carriers can be found in the Handbook of Pharmaceutical excipients, 2nd edition, edited by A. Wade and PJ Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994) found in the reference book.
  • the carrier comprises an excipient such as starch, water or the like; a lubricant such as magnesium stearate or the like; a disintegrating agent such as microcrystalline cellulose; a filler such as lactose; and a binder, Such as pregelatinized starch, dextrin, etc.; sweeteners; antioxidants; preservatives, flavoring agents, spices, etc.;
  • the medicament is in the form of a tablet, a capsule, a pill, a powder, a granule, a syrup, a solution, an emulsion, an injection, a spray, an aerosol, a gel, a cream, a cataplasm, a rubber plaster. Or in the form of a plaster.
  • the 20(R)-ginsenoside Rg3 content is ⁇ 1%, preferably ⁇ 30%, further preferably ⁇ 60%, still more preferably ⁇ 80%, still more preferably ⁇ 98%.
  • Another aspect of the present invention provides a medicament or health care product comprising 20(R)-ginsenoside Rg3 for alleviating and/or treating diabetes.
  • the 20(R)-ginsenoside Rg3 content is ⁇ 1%, preferably 1% to 98%; preferably 30% to 80%, and still more preferably 60%.
  • the 20(R)-ginsenoside Rg3 content is ⁇ 1%, preferably ⁇ 30%, further preferably ⁇ 60%, still more preferably ⁇ 80%, still more preferably ⁇ 98%.
  • the ratio of the weight of the 20(R)-ginsenoside Rg3 to the total weight of the drug or health care product is from 0.01 to 10:100, preferably from 0.1 to 10:100, further preferably from 1 to 10:100. .
  • the medicine or health care product further includes an extract of Astragalus membranaceus, an extract of mulberry leaf, a extract of Radix Rehmanniae, an extract of psoralen, an extract of Cuscuta chinensis, an extract of Polygonum multiflorum, an extract of Polygonatum odoratum, an extract of hawthorn, One or more of Zhimu extract, Angelica extract, Coptidis Rhizoma extract, citrus extract, and pumpkin extract.
  • the medicament can be prepared into various dosage forms by methods well known in the art, such as tablets, capsules, pills, powders, granules, syrups, solutions, emulsions, injections, sprays, aerosols, gels. , cream, cataplasm, rubber plaster or plaster.
  • the present invention also provides a method for treating a diabetic disease comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition of 20(R)-ginsenoside Rg3, wherein the therapeutically effective amount is 0.06 to 12 mg/kg.d, preferably It is 1 to 6 mg/kg.d, and more preferably 1.5 to 3 mg/kg.d.
  • terapéuticaally effective amount as used herein, unless otherwise indicated, is the amount of the agent in need of an effective effect; the “therapeutically effective amount” is adjustable and variable, and is ultimately determined by the medical personnel, the factors considered including the route of administration. And the general nature of the formulation, the recipient's weight, age, etc., and the nature and severity of the condition being treated.
  • the present invention has the following distinct advantages:
  • the present invention excavates a new medicinal value for the known compound 20(R)-ginsenoside Rg3, and uses it for mitigation. It can solve and treat diabetic diseases, and can be prepared into medicines or health foods for relieving or/and treating diabetes, thereby opening up a new field for the application of ginseng medicines.
  • the 20(R)-ginsenoside Rg3 of the invention has strong pharmacological action, has remarkable effects for relieving, regulating and treating diabetes, has quick effect, small toxic and side effects, good safety, can be taken for a long time, and has good medicinal prospects. .
  • the raw materials of the invention have rich sources, low cost, safe clinical use, simple preparation process, can be made into various dosage forms, and have small dosage and convenient use, so it is easy to promote.
  • the present invention can prepare a medicament for relieving and treating diabetes by using a single component of 20(R)-ginsenoside Rg3 active ingredient, and can also use 20(R)-ginsenoside Rg3 and other active ingredients (for example, with astragalus extracting) Extract, mulberry leaf extract, Radix Rehmanniae extract, psoralen extract, Cuscuta chinensis extract, Polygonum multiflorum extract, Polygonatum extract, Hawthorn extract, Zhimu extract, Angelica extract, Coptis extract, Fructus striata extract And one or more of the pumpkin extracts are combined to prepare a compound medicine for treating diabetes.
  • 20(R)-ginsenoside Rg3 active ingredient for example, with astragalus extracting
  • mulberry leaf extract for example, with astragalus extracting
  • Radix Rehmanniae extract psoralen extract
  • Cuscuta chinensis extract Cuscuta chinensis extract
  • Rg3 tablets were prepared according to the following ratios:
  • ginsenoside Rg3 and starch were uniformly mixed, granules were prepared, and talc powder and magnesium stearate were added and uniformly mixed, and then pressed into 10,000 tablets.
  • Rg3 granules were prepared according to the following ratio:
  • Ginsenoside Rg3 (content 63%) 200g
  • the ginsenoside Rg3 and the microcrystalline cellulose were uniformly mixed, and then granulated into bags to prepare 10,000 bags.
  • Rg3 capsules were prepared according to the following ratios:
  • Ginsenoside Rg3 (content 98%) 10g
  • the ginsenoside Rg3 and the starch were uniformly mixed and then encapsulated to prepare 10,000 tablets.
  • Rg3 tablets were prepared according to the following ratios:
  • the ginsenoside Rg3, the astragalus extract and the starch were uniformly mixed and granulated, and talc powder and magnesium stearate were added and mixed, and then pressed into 10,000 tablets.
  • Rg3 capsules were prepared according to the following ratios:
  • Ginsenoside Rg3 (content 63%) 30g
  • the ginsenoside Rg3, the mulberry leaf extract and the starch were uniformly mixed and then encapsulated to prepare 10,000 tablets.
  • Rg3 granules were prepared according to the following ratio:
  • Ginsenoside Rg3, Zhimu extract, Radix Rehmanniae extract and pumpkin powder were mixed and granulated, and then bagged to prepare 10,000 bags.
  • Ginsenoside Rg3 (content >98%), produced by Dalian Fusheng Natural Medicine Development Co., Ltd., batch number: 2012303; ginsenoside Rg3 standard provided by China National Institute for the Control of Pharmaceutical and Biological Products, and HPLC calibration, the content is 98.2%;
  • Positive control drug metformin hydrochloride tablets, Sino-US Shanghai Squibb Pharmaceutical Co., Ltd., batch number: 2011-0412;
  • Streptozotocin sigma company, batch number: 2010-0201.
  • Wistar rats weighing 180 ⁇ 20g, were purchased from Experimental Animal Center of Dalian Medical University, and the quality certificate number was SCXK(13)2012-0002.
  • Twenty qualified rats were selected and divided into 4 groups (normal control group, streptozotocin model group, Rg3 group, positive drug control group). Among them, streptozotocin model group, Rg3 group and positive drug control group were large. The rats were injected with streptozotocin 65 mg/kg 3 days before the start of the experiment.
  • Group 1 was the normal control group, and group 2, 3, and 4 were the streptozotocin treatment model group, and the same amount of pure water was forcibly administered orally.
  • the rats in the normal control group were orally administered with the same amount of purified water; the rats in the model group treated with streptozotocin were given orally with the same amount of purified water; 0.5 mL/time, 8:00 am, 12:00, and 16:00, a total of 3 times.
  • Rats in Rg3 group were orally administered with ginsenoside Rg3 (10 mg/mL), 0.5 mL/time, 3 times in the morning, in the middle and in the evening for 14 consecutive days.
  • the rats in the positive drug control group were orally administered with the positive control drug metformin hydrochloride. Tablets (10 mg/mL), 0.5 mL/time, 3 times in the morning, in the middle and the evening, for 14 consecutive days.
  • the ginsenoside Rg3 dosage is stronger than the hypoglycemic effect of the commonly used hypoglycemic agent metformin.
  • the experimental results show that ginsenoside Rg3 has a hypoglycemic effect on streptozotocin hyperglycemic rats.
  • Ginsenoside Rg3 (content >98%), produced by Dalian Fusheng Natural Medicine Development Co., Ltd., batch number: 2012303; ginsenoside Rg3 standard provided by China National Institute for the Control of Pharmaceutical and Biological Products, and HPLC calibration, the content is 98.2%;
  • Positive control drug pioglitazone hydrochloride tablets (Austin): purchased from Beijing Taiyang Pharmaceutical Co., Ltd., specification: 15mg ⁇ 7 tablets (batch number: H20130520), remove the tablets into fine powder during the experiment, and prepare with distilled water. The solution at a concentration of 0.15 mg/ml was stored at 4 ° C and the shelf life was three days. Remove the liquid before the gavage and place it at room temperature for use.
  • mice Sixty male Sprague-Dawley rats weighing 180-200 g, one week after adaptive feeding, were randomly divided into normal control group (15 rats) and 45 model rats by random weight (computer random number method).
  • the normal control group was given basic feed, and the model was given high-fat and high-calorie feed for 8 weeks. After 8 weeks, fasting and water-free for 12 hours, the model was given a one-time intraperitoneal injection of 2% streptozotocin (STZ) solution 25mg/Kg to establish a type 2 diabetes model with peripheral IR; the normal control group was intraperitoneally injected with the same dose.
  • STZ streptozotocin
  • STZ solution preparation method Weigh a certain amount of STZ, prepare a 2% concentration with 0.1 mol/L citric acid-sodium citrate buffer solution, adjust the pH value to 4.21, and operate in an ice bath.
  • 0.1mol/L citric acid-sodium citrate buffer preparation method 1.05 g of citric acid was weighed and dissolved in 50 ml of ionic sterile water to prepare 0.1 mol/L citric acid solution A. 1.47 g of sodium citrate was weighed and dissolved in 50 ml of ionic sterile water to prepare a 0.1 mol/L sodium citrate solution B.
  • High-sugar and high-fat diet formula: 2% cholesterol, 0.25% sodium citrate, 10% lard, 5% sucrose, 82.75% basic feed.
  • RG3 treatment group 15 positive drug control group (pioglitazone treatment group) and 15 pathological model groups according to fasting blood glucose level.
  • Drug treatment was given for 4 weeks after grouping.
  • Normal control group water was administered by tap water and fed with common feed
  • pathological model group gavage with tap water and high-fat and high-fat diet
  • RG3 treatment group RG3 6mg/kg ⁇ d, and high glucose High-fat diet
  • pioglitazone treatment group pioglitazone hydrochloride 0.3mg/kg ⁇ d was administered intragastrically, and high-sugar and high-fat diet was given at the same time.
  • the blood was taken from the iliac veins. The blood was stored in a vacuum blood collection tube, and blood samples were collected as much as possible. After standing for a while, the serum and plasma were separated, and serum and plasma were separated by centrifugation at 3500 r/min for 10 minutes at 4 ° C, and serum and plasma samples were taken. The product was placed in a 1.5 ml cryotube and stored at -70 °C for testing to check blood glucose and blood insulin levels (insulin test specimens were stored within 35 days of frozen storage); statistical analysis.
  • FBG blood glucose concentration
  • the INS of the serum sample to be tested is assayed for pre-reaction with the antibody for a period of time, and then I 125 -INS is added to compete for the remaining antibody binding sites.
  • the antigen-antibody complex is isolated using an immunosuppressant and the radioactivity count in the complex is determined.
  • the binding amount of I 125 -INS is a function of the content of INS in the sample, and the content of the sample INS can be obtained by data processing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un 20(R)-ginsenoside Rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement du diabète sucré ou son application comme produit de soin de santé. L'invention concerne un médicament pour le soulagement et/ou le traitement du diabète sucré ou un produit de soin de santé renfermant un 20(R)-ginsenoside Rg3.
PCT/CN2015/096991 2015-01-09 2015-12-10 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement du diabète sucré ou son application comme produit de soin de santé et médicament WO2016110168A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510012423X 2015-01-09
CN201510012423.XA CN105816470A (zh) 2015-01-09 2015-01-09 20(R)-人参皂苷Rg3在制备缓解或/和治疗糖尿病药物或保健品中的应用及药物

Publications (1)

Publication Number Publication Date
WO2016110168A1 true WO2016110168A1 (fr) 2016-07-14

Family

ID=56355494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/096991 WO2016110168A1 (fr) 2015-01-09 2015-12-10 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement du diabète sucré ou son application comme produit de soin de santé et médicament

Country Status (2)

Country Link
CN (1) CN105816470A (fr)
WO (1) WO2016110168A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106806641A (zh) * 2016-11-28 2017-06-09 李元英 一种保健品配方

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326771A (zh) * 2001-06-08 2001-12-19 王显勇 一种治疗糖尿病用药物
CN101991627A (zh) * 2009-08-27 2011-03-30 上海新康制药厂 人参皂苷类成分在制备抑制α-葡萄糖苷酶活性药物上的应用
CN103536635A (zh) * 2012-07-16 2014-01-29 郑毅男 一种黑参制备方法及其在治疗糖尿病中的应用
CN103845348A (zh) * 2012-11-30 2014-06-11 富力 20(R)-人参皂苷Rg3在制备痛经药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103845349A (zh) * 2012-11-30 2014-06-11 富力 20(R)-人参皂苷Rg3在制备白癜风药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326771A (zh) * 2001-06-08 2001-12-19 王显勇 一种治疗糖尿病用药物
CN101991627A (zh) * 2009-08-27 2011-03-30 上海新康制药厂 人参皂苷类成分在制备抑制α-葡萄糖苷酶活性药物上的应用
CN103536635A (zh) * 2012-07-16 2014-01-29 郑毅男 一种黑参制备方法及其在治疗糖尿病中的应用
CN103845348A (zh) * 2012-11-30 2014-06-11 富力 20(R)-人参皂苷Rg3在制备痛经药物中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106806641A (zh) * 2016-11-28 2017-06-09 李元英 一种保健品配方

Also Published As

Publication number Publication date
CN105816470A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
Coon et al. Panax ginseng
JP6305407B2 (ja) 免疫を調節する漢方薬組成物及びその製造方法
US10624938B2 (en) Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof
CN106692297B (zh) 一种辅助降血糖的组合物及其制备方法和应用
WO2010037256A1 (fr) Composé diminuant les lipides sanguins et réduisant la glycémie
CN111568948A (zh) 桑提取物在制备改善胰岛功能药物中的应用
WO2016169490A1 (fr) Application de forsythine, dérivé de forsythine et composition de forsythine et lignanes de forsythine dans la préparation d'un médicament pour prévenir et/ou traiter l'hyperlipidémie
EP3403664B1 (fr) Utilisation d'un extrait decistanche tubulosa
CN113730463A (zh) 香连丸产物的新用途
EP3025721B1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'asthme comprenant un extrait de pistacia weinmannifolia j. poiss. ex franch ou une fraction de celui-ci
WO2016110168A1 (fr) 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement du diabète sucré ou son application comme produit de soin de santé et médicament
CN108420890B (zh) 一种具有降血脂作用的组合物及其制备方法
WO2016124080A1 (fr) 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour la prévention et/ou le traitement de l'obésité ou ses applications et médicament associé
CN108066350B (zh) 连翘苷、其衍生物、连翘苷与连翘脂素组合物在制备预防、治疗老年痴呆症药物中的应用
CN114794478A (zh) 一种能降低血压血脂血糖的组合物及应用
CN105616432B (zh) 三七皂苷r4在制备治疗和/或预防过敏性鼻炎药物方面的用途
WO2013056508A1 (fr) Composition pharmaceutique régulant les lipides sanguins et son procédé de préparation
WO2016127771A1 (fr) 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour le soulagement et/ou le traitement des affections rhumatoïdes ou son application comme produit de soin de santé et médicament associé
CN109331093B (zh) 一种植物组合物及其应用
CN108042710B (zh) 一种治疗气阴两虚兼湿热内蕴型2型糖尿病的中药组合物及其应用
WO2020187019A1 (fr) Composition de laxatif de médecine chinoise traditionnelle pour le traitement de la constipation, son procédé de préparation et son application
CN107582866B (zh) 铁皮石斛和氨氯地平在制备治疗高血压药物中的应用方法
CN110898170B (zh) 一种治疗代谢综合征的中药组合物及其制剂
WO2019218537A1 (fr) Composition de chitosane et son procédé de préparation
CN110025011A (zh) 一种增强免疫力的麦冬人参含片

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15876668

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15876668

Country of ref document: EP

Kind code of ref document: A1